These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2495709)

  • 1. Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
    Gulba DC; Fischer K; Barthels M; Polensky U; Reil GH; Daniel WG; Welzel D; Lichtlen PR
    Am J Cardiol; 1989 May; 63(15):1025-31. PubMed ID: 2495709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
    Gulba DC; Bode C; Sen S; Topp J; Fischer K; Wolf H; Hecker H
    Cathet Cardiovasc Diagn; 1992 Jul; 26(3):177-84. PubMed ID: 1617708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
    Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
    J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].
    Gulba DC; Bode C; Topp J; Höpp HW; Westhoff-Bleck M; Rafflenbeul W; Lichtlen PR
    Z Kardiol; 1990 Apr; 79(4):279-85. PubMed ID: 2113330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
    Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis with prourokinase versus urokinase: an in vitro comparison.
    Fox D; Ouriel K; Green RM; Stoughton J; Riggs P; Cimino C
    J Vasc Surg; 1996 Apr; 23(4):657-66. PubMed ID: 8627903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
    Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
    Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
    Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
    J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical study on the thrombolytic effect with different doses of urokinase in acute myocardial infarction. The Collaborative Research Group on Thrombolysis.
    Chin Med J (Engl); 1997 Jan; 110(1):43-6. PubMed ID: 9594320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study.
    Zhao L; Zhao Z; Chen X; Li J; Liu J; Li G;
    Heart Vessels; 2018 May; 33(5):507-512. PubMed ID: 29209778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.